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(RRRs) in VTE events with rivaroxaban against enoxaparin of
70–79% (p < 0.001) following THR and 49% following TKR
(p < 0.001). However, the effect of rivaroxaban relative to alter-
native prophylaxes is also important, including those presently in
development. A systematic literature review identiﬁed RCTs
comparing enoxaparin with warfarin, fondaparinux or dabigat-
ran in THR or TKR. Indirect comparisons of rivaroxaban to
each were conducted, using enoxaparin as common comparator.
Whenever the comparison included more than three studies,
a meta-regression was performed. Results presented are RRRs
from those analyses. RESULTS: Rivaroxaban showed statisti-
cally signiﬁcant reductions in the incidence of key endpoints. In
THR, when compared with fondaparinux, rivaroxaban was
associated with RRRs of 56% in total VTE (p = 0.015) and 89%
(p = 0.015) in symptomatic VTE. When compared with dabiga-
tran, RRRs with rivaroxaban were 86% (p = 0.0018) in symp-
tomatic VTE and 77% (p < 0.001) in total VTE. Similarly, when
compared with warfarin, the RRR in symptomatic VTE with
rivaroxaban was 92% (p = 0.003). In TKR, rivaroxaban pro-
duced 67% (p < 0.001) and 66% (p < 0.001) reductions in total
VTE and deep vein thrombosis (DVT) respectively, versus war-
farin, and 50% (p < 0.001) reductions in total VTE and DVT
versus dabigatran. No other statistically signiﬁcant differences
were found. Importantly for a new anticoagulant, there were
no increases in major bleeding so safety endpoints are unlikely
to inﬂuence cost-effectiveness. CONCLUSION: Rivaroxaban
reduced the incidence of overall or symptomatic VTE events
relative to alternative prophylaxes without increased major
bleeding, reﬂecting a better clinical proﬁle. These risk reductions
may have implications for cost-effectiveness analyses.
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OBJECTIVE: To estimate the cost-effectiveness of the use of
drug-eluting stent compared to bare-metal stent in a cohort of
patients with coronary disease in the Social Security Mexican
Institute (IMSS). METHODS: Cost-effectiveness in a cohort of
patients with ischemic disease with indication of PCI (Percuta-
neous Coronary Intervention). The measure of effectiveness was
the rate of clinical success without major cardiovascular adverse
events. The cost and effectiveness of the treatment were
obtained from clinical follow-up of the cohort from 104
patients in the Cardiology Hospital of IMSS. The micro-costing
technique was used, and the costs come from bases institutional
costs. The results are expressed in US dollars (US$) in 2007.
Given the time horizon of the study (12 months), the discount
rate was not applie. We performed a sensitivity analysis proba-
bilistic, and I think the curve of acceptability. RESULTS: The
61.5% of patients in the cohort used bare-metal stent and
38.5% drug-eluting stent, drug-eluting stent showed the highest
average cost per patient US$15,452.9  12,996.8 compared
with bare-metal stent US$14,254.4  10,826.5. However, the
effectiveness drug-eluting stent found were 97.44% (95%
92.48–100) regarding a bare-metal stent 81.67% (95% CI
71.88–91.46). The RCE was US$17,453.5 in the case of drug-
eluting stent and US$15,829.6 with bare-metal stent, the RCEI
was US$7419. The acceptability curve shows that the treatment
of drug-eluting stent becomes the dominant cost-effectiveness
alternative from WTP US$15,109.9. The probabilistic analysis
shows that drug-eluting stent is more cost effective when it
exceeds US$21,153.8 WTP per patient. CONCLUSION: Drug-
eluting stent is an alternative treatment interventional revascu-
larization with better outcomes in health, and depending from
the availability to pay can be a cost-effectiveness alternative to
the institution.
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OBJECTIVE: To consider the cost-effectiveness of POM statins,
OTC statin and plant sterol/stanol products from the perspective
of middle aged males when used according to current UK guid-
ance for the primary prevention of CVD. METHODS: We used
a Markov-Model to obtain the outcomes for an illustrative
cohort up to 100 years old or death, whichever come sooner. For
the base-case we assumed that all would receive POM statins
from 70 years old and all had to pay for their prescription charge
up to 59 years. The main outcomes for effects were QALYs
(quality-adjusted life-years) and LYG (Life Years Gained). The
main costs included were prescription charges, product costs,
travel costs and gross weekly incomes. The NICE technology
assessment report “Statins for the Prevention of Coronary
Events” published in 2005 was used for transition probabilities
and utility values. Updated costs for 2007 values extracted from
NHS and “HM Revenue & Customs” databases, and average
retail prices of the UK market. RESULTS: Estimated discounted
incremental cost/QALYs were 2970.63, 8026.37 and
16,536.84 for POM statins, OTC statin and plant stanol/sterol
products, respectively. Estimated discounted incremental cost/
LYGs were 5339.02, 14,458.69 and 30,076.96, respec-
tively. Cost/QALYs ranged from 1318.03 to 7854.44,
4289.46 to 11,763.28 and 3961.10 to 29,112.59 for
POM statins, OTC statin and plant sterol/stanol products,
respectively in the univariate sensitivity analyses. CONCLU-
SION: From the patient’s viewpoint, the most cost-effective
intervention is a POM statin (2970.63/QALY). There are con-
siderable differences between the most (POM statins) and the
least (plant sterol/stanol products) cost-effective interventions.
However, for individual patients non-eligibility for free prescrip-
tion or a strong desire to avoid medicalising disease prevention
may overturn the main results.
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OBJECTIVE: To study preventive technologies economic efﬁ-
ciency for patients with cardiovascular diseases in Russia.
METHODS: The study consisted of two parts. The ﬁrst part
involved 303 hypertensive patients without serious s complica-
tions. The second part involved 100 patients with coronary heart
disease (CHD). In both substudies, patients were randomized to
treatment and control groups. Patients of the treatment group
participated in a structured education program for hypertensive
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